State Street’s Aura Biosciences AURA Stock Holding History

State Street’s Portfolio AURA Stock Details AURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.68M	Buy	1,222,984 +258,314	+27%	+$1.85M	﹤0.01%	2755
2026 Q1	$6.45M	Buy	964,670 +38,136	+4%	+$219K	﹤0.01%	2832
2025 Q4	$5.05M	Buy	926,534 +47,663	+5%	+$283K	﹤0.01%	2989
2025 Q3	$5.43M	Buy	878,871 +22,685	+3%	+$148K	﹤0.01%	2972
2025 Q2	$5.36M	Buy	856,186 +63,175	+8%	+$369K	﹤0.01%	2913
2025 Q1	$4.65M	Sell	793,011 -8,812	-1%	-$66.7K	﹤0.01%	2906
2024 Q4	$6.59M	Buy	801,823 +47,020	+6%	+$443K	﹤0.01%	2836
2024 Q3	$6.73M	Buy	754,803 +26,841	+4%	+$230K	﹤0.01%	2817
2024 Q2	$5.5M	Buy	727,962 +158,158	+28%	+$1.16M	﹤0.01%	2888
2024 Q1	$4.47M	Buy	569,804 +63,542	+13%	+$527K	﹤0.01%	2972
2023 Q4	$4.49M	Buy	506,262 +48,902	+11%	+$414K	﹤0.01%	2998
2023 Q3	$4.1M	Buy	457,360 +4,093	+0.9%	+$44K	﹤0.01%	3019
2023 Q2	$5.6M	Buy	453,267 +104,712	+30%	+$1.12M	﹤0.01%	2941
2023 Q1	$3.23M	Buy	348,555 +37,865	+12%	+$393K	﹤0.01%	3150
2022 Q4	$3.26M	Buy	310,690 +12,252	+4%	+$156K	﹤0.01%	3226
2022 Q3	$5.41M	Buy	298,438 +41,692	+16%	+$631K	﹤0.01%	3020
2022 Q2	$3.64M	Buy	256,746 +171,764	+202%	+$2.84M	﹤0.01%	3252
2022 Q1	$1.87M	Buy	84,982 +37,797	+80%	+$720K	﹤0.01%	3596
2021 Q4	$801K	Buy	+47,185	New	+$843K	﹤0.01%	3865

Other funds holding AURA

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

State Street's AURA Position: Q2 2026 in Review

State Street increased its Aura Biosciences (AURA) stake by 27% in Q2 2026, buying an estimated $1.85M and bringing the position to 1,222,984 shares worth $8.68M. The position accounts for ﹤0.01% of the portfolio, ranked #2755.

State Street first reported a position in AURA in Q4 2021 and has held it in 19 quarters since. 146 funds tracked by Wall St. Rank hold AURA as of Q2 2026.

State Street held 1,222,984 shares of Aura Biosciences worth $8.68M as of Q2 2026.
State Street bought 258,314 Aura Biosciences shares in Q2 2026, an estimated $1.85M.
Aura Biosciences made up ﹤0.01% of State Street's portfolio in Q2 2026, its #2755 holding.
State Street first reported a position in Aura Biosciences in Q4 2021 and has held it in 19 quarters since.
146 funds tracked by Wall St. Rank held Aura Biosciences as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.